Related Experiment Videos
Human melanoma: drug resistance
Heike Helmbach1, Pranav Sinha, Dirk Schadendorf
1Klinische Kooperationseinheit für Dermatoonkologie (DKFZ) an der Universitäts-Hautklinik Mannheim, Universität Heidelberg, 68135 Mannheim, Germany.
Summary
Melanoma cells resist chemotherapy due to unknown mechanisms. Understanding apoptosis deficiency is key to overcoming this resistance in advanced malignant melanoma.
Area of Science:
- Oncology
- Cancer Biology
- Dermatology
Background:
- Advanced malignant melanoma presents a poor prognosis due to chemotherapy ineffectiveness.
- Melanoma cell resistance to antineoplastic agents is a significant clinical challenge.
- The precise reasons for the chemoresistant phenotype in melanoma remain largely unknown.
Purpose of the Study:
- To review known drug resistance mechanisms in melanoma.
- To discuss the role of apoptosis and apoptotic deficiency in chemoresistance.
- To highlight the complexity of apoptotic pathways and their regulation.
Main Methods:
- Literature review of established drug resistance mechanisms.
- Analysis of apoptosis induction by anticancer drugs.
- Discussion of molecular alterations in apoptotic pathways (e.g., Bcl-2 family, Hsp family).
Main Results:
- Chemotherapy resistance in melanoma involves mechanisms like altered drug transport and enzyme activity.
- Most anticancer drugs induce apoptosis in susceptible cells.
- Deficiency in apoptosis, caused by alterations in apoptotic pathways, contributes significantly to chemoresistance.
Conclusions:
- Apoptosis deficiency is a critical factor in melanoma's chemoresistance.
- Understanding the molecular regulation of apoptosis is essential for developing effective melanoma treatments.
- Targeting apoptotic pathways may offer novel therapeutic strategies for advanced melanoma.